Formation Bio Inc., a startup using artificial intelligence to speed up drug development, today announced that it has closed a mammoth $372 million investment. Andreessen Horowitz led the Series D ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Founders: Benjamine Liu (CEO), Linhao Zhang Launched: 2016 Headquarters: New York City Funding: $600 million Valuation: $1.7 billion (PitchBook) Key Technologies: Artificial intelligence, deep neural ...

NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Formation Bio and Jiangsu Chia Tai Feng Hai Pharmaceutical Co., LTD. (CTFH) today announced Formation Bio's acquisition of worldwide rights, excluding Greater ...

Formation Bio is inking a deal worth more than $600 million in biobucks for ex-China rights to a next-gen immunology asset from Lynk Pharmaceuticals. Lynk’s program will be developed by Formation’s ...

HANGZHOU, China and SHANGHAI and BOSTON, Dec. 10, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals") and Formation Bio today announced Formation ...

Paris, New York, N.Y., and San Francisco, CA, May 21, 2024. Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to ...

Formation Bio CEO Benjamine Liu joins 'Fast Money' as Formation comes in at #37 on the Disruptor 50 list. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get ...

Tuesday, French drugmaker Sanofi SA (NASDAQ:SNY) announced its collaboration with OpenAI and Formation Bio to accelerate drug development projects. Also Read: Drugmaker Sanofi’s Strong Dupixent And ...

Formation Bio, a startup focused on applying AI to drug development with backing from OpenAI CEO Sam Altman, has raised over a quarter-billion dollars to support its ambitious product roadmap.

NEW YORK, Sept. 18, 2025 /PRNewswire/ -- Formation Bio, the AI-native pharmaceutical company revolutionizing drug development, today announced the appointment of four world-class leaders to its senior ...

"We are excited to partner with Formation Bio to advance LNK01006 into the clinic," said Zhao-Kui (ZK) Wan, CEO of Lynk Pharmaceuticals. "Formation Bio's experienced clinical development team and ...